Rh-sensitization

When maternal and fetal blood mix during pregnancy or delivery, the Rh-negative mother's immune system is triggered to develop antibodies against the antigens in her baby's blood, if Rh-positive. This is called Rh-sensitization or alloimmunization.1

Numerous conditions or circumstances can allow maternal and fetal blood to mix, resulting in Rh-sensitization. This includes:1

  • Delivery
  • Hydrops fetalis
  • Miscarriage
  • Amniocentesis
  • Chorionic villus sampling
  • Abortion
  • Maternal blood transfusions

Typically, only a small number of antibodies are produced in the first pregnancy. During delivery, however, the mother's immune system becomes sensitized to the Rh factor. In subsequent pregnancies, the mother produces a greater number of antibodies, which can cross the placenta to destroy the fetal red blood cells and create significant health risks for the baby.

An Rh-negative mother needs to receive anti-D IgG treatment during her first pregnancy and immediately following delivery to prevent Rh-sensitization that could endanger an Rh-positive fetus, particularly in future preganancies.

  1. Myle AK, Al-Khattabi GH. Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects. Pediatric Health Med Ther. 2021 Oct 7;12:491-498. doi: 10.2147/PHMT.S327032. PMID: 34675752; PMCID: PMC8504549.
  2. Zipursky A, Paul V. The global burden of Rh disease. Arch Dis Child Fetal Ed. March 2011 Vol 96 No 2: F84-85.
Expand

Important Safety Information

Rhophylac®, Rho(D) Immune Globulin Intravenous (Human), is a blood-derived injection given to women with an Rh-negative who might have an incompatible pregnancy—that is, who may be carrying an unborn child with Rh-positive blood. If a woman in such a pregnancy is not treated, the result could be “isoimmunization,” a condition in which the mother’s Rh-negative blood produces antibodies that could attack the unborn child’s Rh-positive blood cells, potentially creating serious health problems for the unborn child and any future children of the mother.

Rhophylac is given by healthcare providers as routine protection against isoimmunization, typically during weeks 28-30 of pregnancy, often with readministration within 72 hours following childbirth. It is also given in cases of obstetric complications, invasive procedures during pregnancies, incomplete pregnancies, and obstetric manipulative procedures in certain pregnant women. Rhophylac is also used in Rh-negative individuals who have received incompatible blood components containing Rh-positive red blood cells. For suppression of Rh isoimmunization, Rhophylac can be administered intravenously or intramuscularly.

Rhophylac must not be administered to the newborn infant(s) of the mother that received Rhophylac after giving birth. You should not receive Rhophylac if you have had a previous serious allergic reaction to Rhophylac or other human blood products. It should not be given if you are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Your physician will do a blood test to assess your situation regarding IgA.

The most common side effects for patients who received Rhophylac for Rh isoimmunization are nausea, dizziness, headache, injection-site pain, and feeling unwell. Discuss with your doctor any reaction or symptom you experience after administration of Rhophylac that concerns you.

Rhophylac is made from donated human blood. The risk of transmission of infections agents, including viruses, cannot be completely eliminated.

Immunoglobulin administration can transiently interfere with your response to live vaccines, such as measles, mumps, rubella, and varicella. Tell your doctor if you plan to receive a vaccine after receiving Rhophylac.

Please see full prescribing information for Rhophylac, which includes a boxed warning that does not apply to use of Rhophylac in pregnancy or in cases of incompatible transfusions.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.


Collapse
Rhophylac is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Rhophylac® is a registered trademark of CSL Behring AG.
Other trademarks mentioned are the property of their respective owners.
CSL Behring
© 2026 CSL Behring. The product information presented on this site is intended for US residents only. US-RHO-0027-MAR24